<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Sorci L</submitter><funding>NIAID NIH HHS</funding><pagination>39490-9</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC2998121</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>285(50)</volume><pubmed_abstract>Enzymes involved in the last steps of NAD biogenesis, nicotinate mononucleotide adenylyltransferase (NadD) and NAD synthetase (NadE), are conserved and essential in most bacterial species and are established targets for antibacterial drug development. Our genomics-based reconstruction of NAD metabolism in the emerging pathogen Acinetobacter baumannii revealed unique features suggesting an alternative targeting strategy. Indeed, genomes of all analyzed Acinetobacter species do not encode NadD, which is functionally replaced by its distant homolog NadM. We combined bioinformatics with genetic and biochemical techniques to elucidate this and other important features of Acinetobacter NAD metabolism using a model (nonpathogenic) strain Acinetobacter baylyi sp. ADP1. Thus, a comparative kinetic </pubmed_abstract><journal>The Journal of biological chemistry</journal><pubmed_title>Genomics-driven reconstruction of acinetobacter NAD metabolism: insights for antibacterial target selection.</pubmed_title><pmcid>PMC2998121</pmcid><funding_grant_id>R01 AI066244</funding_grant_id><pubmed_authors>de Crecy Lagard V</pubmed_authors><pubmed_authors>Gerdes S</pubmed_authors><pubmed_authors>Osterman A</pubmed_authors><pubmed_authors>Sorci L</pubmed_authors><pubmed_authors>Blaby I</pubmed_authors><pubmed_authors>De Ingeniis J</pubmed_authors><pubmed_authors>Raffaelli N</pubmed_authors></additional><is_claimable>false</is_claimable><name>Genomics-driven reconstruction of acinetobacter NAD metabolism: insights for antibacterial target selection.</name><description>Enzymes involved in the last steps of NAD biogenesis, nicotinate mononucleotide adenylyltransferase (NadD) and NAD synthetase (NadE), are conserved and essential in most bacterial species and are established targets for antibacterial drug development. Our genomics-based reconstruction of NAD metabolism in the emerging pathogen Acinetobacter baumannii revealed unique features suggesting an alternative targeting strategy. Indeed, genomes of all analyzed Acinetobacter species do not encode NadD, which is functionally replaced by its distant homolog NadM. We combined bioinformatics with genetic and biochemical techniques to elucidate this and other important features of Acinetobacter NAD metabolism using a model (nonpathogenic) strain Acinetobacter baylyi sp. ADP1. Thus, a comparative kinetic </description><dates><release>2010-01-01T00:00:00Z</release><publication>2010 Dec</publication><modification>2025-04-04T20:12:53.823Z</modification><creation>2019-03-27T00:37:13Z</creation></dates><accession>S-EPMC2998121</accession><cross_references><pubmed>20926389</pubmed><doi>10.1074/jbc.M110.185629</doi><doi>10.1074/jbc.m110.185629</doi></cross_references></HashMap>